Thelansis

PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) Market Outlook Thelansis’s “PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Whic...

  PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) Market Outlook Thelansis’s “PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) Overview Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a hereditary cardiac disorder characterized by impaired function of the right ventricle (RV) and the occurrence of ventricular arrhythmias, which can ultimately lead to sudden cardiac death. The condition is characterized by the replacement of ca...

  Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a hereditary cardiac disorder characterized by impaired function of the right ventricle (RV) and the occurrence of ventricular arrhythmias, which can ultimately lead to sudden cardiac death. The condition is characterized by the replacement of cardiomyocytes with fibrofatty tissue. ARVD/C is typically inherited in an autosomal dominant manner, but it exhibits incomplete penetrance, and the expression of the disease varies significantly with age. In rare cases, autosomal recessive inheritance can occur with or without cutaneous involvement. The progressive fibrotic replacement process leads to electrical instability, increasing the risk of syncope and sudden cardiac death, or causing alterations in cardiac function, resembling dilated cardiomyopathy, which may result in right- or bi-ventricular heart failure. The diagnosis of ARVD/C is challenging and relies on applying the 2010 Task Force criteria, which consid...